Top 10 Value Stocks To Buy For 2018


China has set an economic growth target range of 6.5% to 7% for this year as the central government struggles to manage a slowdown in the world’s second-largest economy.

The low end of the new growth goal is a few notches below what China posted last year. Gross domestic product expanded by 6.9% in 2015, its slowest pace in 25 years and a hair slower than the government’s 7% target.

This is the first time since 1995 that Beijing has announced a target range for economic growth. It shows the government moving away from its previous approach of setting specific numbers to hit.


Experts have questioned the value of the headline growth goal, saying it encourages local and provincial officials to distort their numbers to please Beijing.

After decades of breakneck expansion, China’s economy is now decelerating. The government is trying to shift the growth engine away from a reliance on manufacturing and debt-fueled investment toward the services sect or and consumer spending.

Top 10 Value Stocks To Buy For 2018: PetroShare Corp. (PRHR)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Just one company joined the calendar, micro-cap gunshot detector ShotSpotter (Pending:SSTI), and one micro-cap company filed, DJ Basin E&P PetroShare (OTCQB:PRHR). We had expected more JOBS-Act filers this week as Monday marked the first day to file for companies preparing for post-Memorial Day launches.

Top 10 Value Stocks To Buy For 2018: RadiSys Corporation(RSYS)

Advisors’ Opinion:

  • [By Lisa Levin]

    RadiSys Corporation (NASDAQ: RSYS) was down, falling around 18 percent to $2.95 after the company lowered its sales forecast for the second quarter. The company now expects Q2 sales of $35 million, versus earlier outlook of $41 million to $47 million.

  • [By Lisa Levin]

    RadiSys Corporation (NASDAQ: RSYS) was down, falling around 18 percent to $2.97 after the company lowered its sales forecast for the second quarter. The company now expects Q2 sales of $35 million, versus earlier outlook of $41 million to $47 million.

Top 10 Value Stocks To Buy For 2018: Paragon Offshore plc (PGNPQ)


Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Paragon Offshore’s (OTCPK:PGNPQ) former management’s audacious efforts to omit parts of the senior secured lenders by deeming them unimpaired and instead pay out the majority of the company’s cash to junior unsecured bondholders by presenting a set of entirely unrealistic business forecasts to the court. Fortunately, in case of Paragon Offshore, the bankruptcy judge recognized the framing and accordingly denied confirmation of the company’s plan of reorganization, effectively sending Paragon Offshore back to the drawing board. Consequently, management was ousted after the failure. I have covered the Paragon Offshore saga in a series of articles over the past few quarters, so interested investors might want to take a look at this highly fascinating and still evolving case study.

  • [By SEEKINGALPHA.COM]

    With even brand new rigs struggling to find work, the jig was soon up for owners of old equipment, like Paragon Offshore (OTCPK:PGNPQ), which is currently undergoing its second debt restructuring in less than three years of independent existence. Likewise, drillers with a fondness for aggressive use of debt were soon in trouble, most notably, former high-flier Seadrill (SDRL) and its little brother North Atlantic Drilling (NADL), which will no doubt file for restructuring within months. As a consequence of the crisis, the OSD industry now has a number of participants without a large debt burden, either new entrants like Borr Drilling, or established competitors that have had debt reduced in a restructuring, such as Ocean Rig (ORIG), to be followed within this year by others, almost certainly including each of SDRL, NADL, and Pacific Drilling (PACD).

Top 10 Value Stocks To Buy For 2018: DIRECTV(DTV)


Advisors’ Opinion:

  • [By Christopher Freeburn]

    Service disruptions on DirecTV’s (DTV) website temporarily interfered with subscribers’ ability to stream National Football League (NFL) games online for the last two Sundays.

Top 10 Value Stocks To Buy For 2018: Fitbit, Inc.(FIT)

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap fitnessdevice stock and wearables stockFitbit Inc (NYSE: FIT) started off as a high flyer after its 2015 IPO, but those highflying days have largely ended as you can see from its long term performance chart:

  • [By Ashley Moore]

    We saw it with GoPro Inc. (Nasdaq: GPRO) and Fitbit Inc. (NYSE: FIT). Both are trading about 90% below their post-IPO peak prices.

    “The thought that any sane investor would buy Snapchat is frightening,” said Money Morning Capital Wave Strategist Shah Gilani. “Buying shares in SNAP is like trying to pick up nickels in front of buses.”

  • [By Evan Niu, CFA]

    Times are tough for Fitbit (NYSE:FIT), and investor pessimism is on the rise. According to a report by financial analytics company S3 Partners (via Business Insider), short interest in Fitbit has utterly skyrocketed in the first couple of weeks of the year. “Short sellers have added more than 20 million shares over the first two weeks of 2017, bringing the total amount of shares on loan to close to 50% of float,” according to S3.

  • [By Leo Sun]

    Under Armour (NYSE:UA) (NYSE:UAA), Fitbit (NYSE:FIT), and GoPro (NASDAQ:GPRO) were all terrible stocks to own over the past year. Under Armour and Fitbit were both cut in half, and GoPro plummeted nearly 40%.

Top 10 Value Stocks To Buy For 2018: VIVUS, Inc.(VVUS)

Advisors’ Opinion:

  • [By Keith Speights]

    Arena is out of the obesity drug business, but what about Orexigen Therapeutics (NASDAQ:OREX) or VIVUS (NASDAQ:VVUS)? The problem is that they’re both too dependent on their respective obesity drugs, Contrave and Qsymia. Neither of the drugs have performed up to expectations.

  • [By Peter Graham]

    A long term chart shows Arena Pharmaceuticals along with its small capobesitytreatmentpeers EnteroMedics Inc (NASDAQ: ETRM), Orexigen Therapeutics, Inc (NASDAQ: OREX) and VIVUS, Inc (NASDAQ: VVUS) all causing severe weight loss for investor portfolios:

Top 10 Value Stocks To Buy For 2018: Potlatch Corporation(PCH)

Advisors’ Opinion:

  • [By Lisa Levin]

    Here is the list of stocks going ex-dividend on Friday.


    Douglas Dynamics Inc (NYSE: PLOW) – $0.2350 dividend, 2.9183 percent yield Tiffany & Co. (NYSE: TIF) – $0.4500 dividend, 2.6758 percent yield PulteGroup, Inc. (NYSE: PHM) – $0.0900 dividend, 1.7078 percent yield Leidos Holdings, Inc. (NYSE: LDOS) – $0.3200 dividend, 3.0851 percent yield Tupperware Brands Corporation (NYSE: TUP) – $0.6800 dividend, 4.1756 percent yield Hudson Pacific Properties Inc (NYSE: HPP) – $0.2000 dividend, 2.36

Top 10 Value Stocks To Buy For 2018: DSP Group Inc.(DSPG)


Advisors’ Opinion:

  • [By Lisa Levin]

    Technology shares rose by 2 percent in the US market on Friday. Top gainers in the sector included Fabrinet (NYSE: FN), and DSP Group, Inc. (NASDAQ: DSPG).

Top 10 Value Stocks To Buy For 2018: Dynavax Technologies Corporation(DVAX)

Advisors’ Opinion:

  • [By Lisa Levin]

    Dynavax Technologies Corporation (NASDAQ: DVAX) shares shot up 73 percent to $15.99 as the company announced that the Vaccines and Related Biological Products Advisory Committee of the U.S. Food and Drug Administration voted 12-1 in support of the company’s Hepatitis B vaccine, HEPLISAV-B. RBC Capital upgraded Dynavax from Sector Perform to Outperform.

  • [By Lisa Levin]

    Dynavax Technologies Corporation (NASDAQ: DVAX) shares were also up, gaining 17 percent to $6.88 after the company on Friday presented updated data for SD-101 in combination with KEYTRUDA.

  • [By Lisa Levin] Gainers Loxo Oncology Inc (NASDAQ: LOXO) rose 32.7 percent to $65.00 in pre-market trading after the company reported that larotrectinib trial demonstrated 76 percent confirmed objective response rate. Dynavax Technologies Corporation (NASDAQ: DVAX) shares rose 22 percent to $7.20 in the pre-market trading session after the company on Friday presented updated data for SD-101 in combination with KEYTRUDA. Puma Biotechnology Inc (NASDAQ: PBYI) rose 21.7 percent to $99.75 in pre-market trading as the company disclosed positive PB272 Phase 2 data from TBCRC 022 trial at ASCO17. Helios and Matheson Analytics Inc (NASDAQ: HMNY) shares rose 20.7 percent to $3.21 in pre-market trading after the company reported that RedZone has acquired all the assets of Trendit including three technology patents. Forestar Group Inc. (NYSE: FOR) rose 13.1 percent to $16.05 in pre-market trading after D.R. Horton, Inc. (NYSE: DHI) proposed to buy 75 percent of Forestar Group for $16.25 per share in cash. TG Therapeutics Inc (NASDAQ: TGTX) shares rose 12 percent to $15.50 in pre-market trading after the company said Phase 3 GENUINE trial met primary endpoint with TG-1101 + ibrutinib increasing overall response rate by >70 percent versuss ibrutinib alone. Gigamon Inc (NYSE: GIMO) gained 10.8 percent to $43.55. Reuters reported that Gigamon is exploring a potential sale. BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) rose 8.7 percent to $6.00 in pre-market trading after the company announced Rapivab pediatric sNDA acceptance by the FDA. Array Biopharma Inc (NASDAQ: ARRY) rose 7.2 percent to $8.77 in pre-market trading after gaining 5.68 percent on Friday. Ehi Car Services Ltd (ADR) (NYSE: EHIC) shares rose 6.4 percent to $10.76 in pre-market trading. eHi Car Services posted Q1 earnings of $0.06 on sales of $89.43 million. Skyworks Solutions Inc (NASDAQ: SWKS) rose 5.9 percent to $114.79 in pre-market trading after gaining 0.69 percent on Friday. Sorl Auto
  • [By WWW.KIPLINGER.COM]

    Add Dynavax Technologies Corp. (DVAX) to the list of biotech stocks to watch on or a little before Dec. 15. Thats when the company is going to get a yay or nay from the Food & Drug Administration about Heplisav-B as a treatment for hepatitis B in people with type 2 diabetes

Top 10 Value Stocks To Buy For 2018: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Amgen (AMGN) has tumbled 3.6% to $158.65 after beating earnings forecasts but missing on sales.


    Buffalo Wild Wings (BWLD) has dropped 3% to $157.51 after its earnings fell short of the Street consensus.

  • [By Ben Levisohn]

    Biotech stocks have been particularly unloved during the past year, with the iShares Nasdaq Biotech Index ETF (IBB) gaining just 7% to the S&P 500′s 20% rise. Today, however, Amgen (AMGN) is getting a lot of love from the market after releasing Street beating earnings and reporting that its anti-cholesterol drug reduced heart attacks.

  • [By Maxx Chatsko]

    Shares of Radius Health (NASDAQ:RDUS) rose over 20% Monday morning after Amgen (NASDAQ:AMGN) announced worrisome complications were discovered during a phase 3 trial for its osteoporosis drug candidate, Evenity. While the drug candidate met its primary endpoint in a more than 4,000-patient phase 3 study, a high rate of serious heart-related side effects were discovered. The drug was previously expected to gain marketing approval from the U.S. Food and Drug Administration in July, but that decision will now be delayed by up to a year or more, if the drug is approved at all.

  • [By Ben Levisohn]

    After years of rising and falling in tandem, the biotech sector is all about stock picking now. Credit Suisse analyst Alethia Young and team, for instance, upgraded Regeneron Pharmaceuticals (REGN), and added Celgene (CELG) to its Focus List today. But Amgen (AMGN) wasn’t so lucky as Young cut it to Neutral from Outperform. She explains why:

  • [By Ben Levisohn]

    What do I mean? Regeneron’s dropped 14% during the last three months, the result of a patent suit with Amgen(AMGN) over its anti-cholesterol drug Praluent, which a judge had set it wouldn’t be able to sell in the U.S.Then last night, there was finally good news: Ajudge ordered a stay, which would allow Regeneron to sell Praluent, and resulted in a 2% pop in its shares last night after the market close. But then Regeneron reported earnings, and while profits of $3.04 cents a share metthe Street consensus, Regeneron missed on sales and offered disappointing guidance. That caused Regeneron shares to sink 2.1% in pre-open trading.

  • [By WWW.THESTREET.COM]

    That’s why Cramer said he’ll be listening for news coming from Celgene (CEL) , Amgen (AMGN) , Allergan (AGN) , an Action Alerts PLUS holding, and Regenron (REGN) , all of which are set to present. Of the four, Cramer said he’s sticking with Allergan and Amgen.